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Abstract Analysis of developmental angiogenesis can
help to identify regulatory networks, which also contribute
to disease-related vascular growth. Vascular endothelial
growth factors (Vegf) drive angiogenic processes such as
sprouting, endothelial cell (EC) migration and prolifera-
tion. However, how Vegf expression is regulated during
development is not well understood. By analyzing devel-
opmental zebrafish angiogenesis, we have identified
Metallothionein 2 (Mt2) as a novel regulator of vegfc
expression. While Metallothioneins (Mts) have been
extensively analyzed for their capability of regulating
homeostasis and metal detoxification, we demonstrate that
Mt2 is required for EC migration, proliferation and
angiogenic sprouting upstream of vegfc expression. We
further demonstrate that another Mt family member cannot
compensate Mt2 deficiency and therefore postulate that
Mt2 regulates angiogenesis independent of its canonical Mt
function. Our data not only reveal a non-canonical function
of Mt2 in angiogenesis, but also propose Mt2 as a novel
regulator of vegfc expression.
Keywords Vegfc  Angiogenesis  Endothelial cell
migration  TALEN  Nonsense-mediated decay 
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Introduction
Growth of blood vessels during development as well as in
the adult organism is a tightly regulated process, which is
controlled by endothelial cell (EC) behaviors such as cell
migration, proliferation and differentiation. Misregulation
of vascular growth not only contributes to ischemic con-
ditions, but overgrowth also directly aggravates diseases
such as growth and metastasis of cancers or age-related
macular degeneration.
Vascular endothelial growth factors (Vegfs) and their
Vegf receptors (VEGFR-1/Flt1, VEGFR-2/Kdrl-Kdr and
VEGFR-3/Flt4) are the major regulators of vascular growth
processes [1–3].
While VEGFA and VEGFR-2 (Kdrl in zebrafish) mainly
regulate angiogenic processes such as sprouting and
remodeling of vessels [4, 5], VEGFC and VEGFR-3 have
mainly been recognized for their role in regulating devel-
opment of the lymphatic endothelial system [6–8]. Vegfr3/
flt4-deficient zebrafish completely lack lymphatic vessels
but show no major defects in blood vessel growth
[9]. VEGFR3-deficient mice die of defective vascular
development before the lymphatic system becomes estab-
lished [10]. Vegfc mutant mice as well as zebrafish lack a
lymphatic system [11, 12]. Angiogenesis defects observed
in vegfc zebrafish mutants include failure in EC migration
[during formation of the primordial hindbrain channels
(PHBCs)] [11] as well as reduced EC proliferation [in the
common cardinal veins (CCVs)] [13].
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However, VEGFA as well as VEGFC expression are
both upregulated in various tumors and their misregulation
is involved in other diseases; therefore, understanding the
mechanisms regulating their expression are of clinical
relevance [14, 15].
Within cultured fibroblast or cancer cells, VEGFCmRNA
expression was shown to be upregulated by cytokines (In-
terleukin-1a or interleukin-1b, or Tumor necrosis factor-a)
[16] and growth factors (Platelet derived growth factor,
Epidermal growth factor and Transforming growth factor-b)
[17], but not by Hypoxia-inducible factor-1a (HIF1a) [18].
The optical clarity of the externally developing zebrafish
embryos is one of the many advantages for using this
model for the analysis of vascular development. The
growing vasculature can easily be visualized in vivo by
endothelial-specific transgenic fluorophore expression [19].
The vascular anatomy of zebrafish embryos has a high
structural homology to other vertebrates [20, 21]. Similarly,
most signaling pathways regulating vascular development
are conserved between zebrafish and mammals [22, 23]. A
functional circulatory system including a primitive heart is
already established in the zebrafish embryo by 24 h post-
fertilization (hpf).
Additionally, recent advances in genome editing using
Transcription activator-like effector nucleases (TALENs) or
Cas9 nucleases [24, 25] enabled gene-specific targeting in
zebrafish.
We performed gene expression analyses to identify
novel regulators of angiogenesis in zebrafish embryos and
thereby identified metallothionein 2 (mt2) as a candidate.
MTs are low-molecular-weight and cysteine-rich pro-
teins, which are conserved throughout the animal kingdom.
There are four classes of mammalian Mt genes, Mt1–4 [26,
27], and two mt genes in zebrafish, mt2 and metalloth-
ionein-B-like (mtbl) [28, 29].
The main function of MTs is the regulation of home-
ostasis, such as the protection against oxidative stress or
metals. Both heavy and trace metals such as zinc, copper or
iron can be chelated via sulfur-based clusters [30, 31].
However, MTs also display non-canonical functions in
angiogenesis and pathological conditions. Mt1 and Mt2 are
very similar and the best characterized genes of the MT
family, which can act as tumor suppressors [32] and have
cardio- and neuroprotective functions [33–35]. Mice defi-
cient for bothMt1 andMt2 are viable and show beside their
greater sensitivity to metals no major developmental
defects [36, 37]. When challenged by femoral artery liga-
tion or cortical freeze injury, these Mt1/2 knockout mice
show impaired angiogenesis and wound healing [38–40].
MT3 is important for cell growth [41], and its expression is
downregulated in a carcinoma cell line [42]. MT3 also has
a critical role in the recovery of the brain, since Mt3-de-
ficient mice show increased oxidative stress and apoptosis
upon cortical freeze lesion [43]. The non-inducible Mt4 is
expressed in epithelial tissues and has only been shown to
detoxify of metals [30, 44].
However, how MTs exert their non-canonical functions,
such as the regulation of angiogenic processes, is not
understood.
Here, we used zebrafish as a model to analyze the role of
Mt in angiogenesis. We generated Mt2-deficient zebrafish
embryos by performing antisense morpholino-oligonu-
cleotide (MO)-mediated gene knockdown as well as by
using TALEN to generate zebrafish mt2 mutants. Using
in vivo time-lapse analysis, we show that mt2 deficiency
leads to striking angiogenesis defects, especially to defec-
tive formation of the PHBCs. Furthermore, we demonstrate
that Mt2 acts upstream of vegfc expression in regulating
EC migration and proliferation. This regulation of angio-
genesis represents a non-canonical function of Mt2, since
another Metallothionein family member (Mtbl) cannot
regulate vegfc expression.
Materials and methods
Zebrafish maintenance and strains
Zebrafish embryos were maintained at 28.5 C under
standard husbandry conditions [45]. Zebrafish lines used
were Tg(kdrl:EGFP)s843 [46], Tg(fli1a:EGFP)y1 [47] and
Tg(fli1a:nEGFP)y7 [48]. The vegfchu6410 allele encodes a
stop codon at amino acid position 107 (L107X) [49].
Generation of the mt2 mutant transgenic zebrafish
line using transcription activator-like effector
nucleases (TALENs)
TALENs were assembled using the Golden Gate method
[50]. For targeting the mt2 locus, a 50 RVD (NH–NG–NH–
NH–NI–NG–NI–HD–NG–HD–NG–HD–NG–NH (DNA
sequence GTGGATACTCTCTGG)) and a 30 RVD (NI–
HD–NG–HD–NG–NG–NH–NH–HD–NI–HD–NI–NG–NG
(DNA sequence ACTCTTGGCACATTC)) were generated
with a spacer of 16 bp (AAAAATGGACCCCTGC) to
target exon 1. An AvaII (New England BioLabs) restriction
site within the spacer region was used for genotyping of
putative founders. mRNA was generated using the T3
mMessage mMachine Kit (Ambion) and injected using
100 pg of the TALEN mix.
mRNA and morpholino (MO) injections
MOs blocking either translation (MO) or RNA splicing
(spbMO) were obtained from Gene Tools and are as
follows:
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mt2 MO: 50-GGTCCATTTTTCCAGAGAGTATCCT
(5 ng) and mt2 spbMO: 50-AGCTGAAACACTTACTCTT
GGCACA (7–10 ng), targeting mt2 (BC152694.1); mtbl
MO: 50-CTGGTCCATCTTTACACCGTAGGTC and mtbl
spbMO: 50-AGTTAATCGGCTCACTTTTCTTGTC (both
13 ng) targeting mtbl (NM_001201469.1), upf1 spbMO: 50-
TTTTGGGAGTTTATACCTGGTTGTC (0.1 ng) [51] and
smg1 spbMO: 50-AACCATTGGTTTGTTACCTGGTGCA
(12.5 ng) [51] and standard control MO: 50-CCTCTTACC
TCAGTTACAATTTATA.
For overexpression experiments, the mt2 sequence was
amplified from 24 hpf cDNA and cloned into the pCS2?
vector for in vitro RNA synthesis using the following
primers: mt2fwd 50-AGACGAATTCGCTCCACCATG
GACCCCTGCGAATGTGC and mt2rev 50-AGACCTCGA
GTCATTGACAGCAGCTGGAGC.
Similarly, mtbl was cloned into the pCS2? vector using
mtblfwd 50-AGACGAATTCGCTCCACCATGGACCAGT
GTAACTGCTC and mtblrev 50- AGACCTCGAGTCATT
TGCAGCAGTGTGTGG.
The mRNA was synthesized using SP6 mMessage
mMachine Kit (Ambion). For all experiments, the injection
was done into the yolk of 1-cell-stage zebrafish embryos,
and 0.05 % phenol red (Sigma) was added to the injection
solution.
Injection amounts per embryo were as follows: 500 pg
mt2 mRNA, 100 pg mtbl mRNA, 100 pg to 500 pg H2B-
cherry mRNA [52], 200 pg vegfc mRNA [53] and 200 pg
sFLT4 mRNA [54].
RNA and DNA isolation, qPCR analysis
and genotyping
RNA from WT, mutants and MO-injected embryos was
isolated with Trizol reagent, and cDNA was generated by
SuperScript II reverse transcriptase (Invitrogen).
The cDNA was analyzed with real-time quantitative
PCR (qPCR) using Power SYBR Green (Applied Biosys-
tems) and the following primers: b-actinfwd 50-CTGGAC
TTCGAGCAGGAGAT and b-actinrev 50-GCAAGATTC
CATACCCAGGA (156 bp amplicon); vegfcfwd 50-GCAG
GAACATCAGCACTTCA and vegfcrev 50-GTGTGGTTG
GCGAAGCTTAT (103 bp amplicon); fli1afwd 50-CTCAG
GGAAAGTAGCTCATCG and fli1arev 50-CTTTTCCGC
TGTGCATGTT (139 bp amplicon); myod1fwd 50-TCTGA
TGGCATGATGGATTT and myod1rev 50-TTATTA
TTCCGTGCGTCAGC (110 bp amplicon). For qPCR at
least two different cDNA samples were generated and
analyzed. Experiments were performed at least three times.
The knockdown efficiency of the mt2 splice MO was
validated with reverse transcription PCR (RT-PCR) and
primers mt2fwd 50-ATGGACCCCTGCGAATGTGC and
mt2rev 50-TCTTCTTGCAGGTAGTACACTG (spliced
amplicon 91 bp, non-spliced amplicon 185 bp). The func-
tionality of the mtbl splice MO was analyzed with mtblfwd
50-GACCAGTGTGACTGCTCCAA and mtblrev 50-TGCA
GGATTTCTCCTTGTCC (spliced amplicon 169 bp, non-
spliced amplicon 327 bp).
DNA was extracted using lysis buffer (10 mM Tris–
HCl, 50 mM KCl, 0.3 % Tween 20, 0.3 % Nonidet P-40,
pH 8.3) with 0.5 lg/ll proteinase K (Roche) overnight at
55 C, followed by 10 min denaturation at 95 C.
The genotype of the mt2mu290, the mt2mu292 and the
mt2mu289 mutants was analyzed with primers mt2fwd 50-T
CTTCTTGCAGGTAGTACACTG and mt2rev 50-TAAAA
GCAGAGCACAAACACG and the restriction enzyme
AvaII.
The genotype of the vegfchu6410 zebrafish mutants was
analyzed in a multiplex PCR with WT and mutant zebra-
fish-specific inner and outer primers. As inner primers
vegfcfwd 50-CTTTCATCAATCTTGAACTTTT (WT
specific) and vegfcrev 50-TAAATTAATAGTCAC
TCACTTTACT (mutant specific with one mismatch) were
used and as outer primers vegfcfwd 50-GATGAACTCATG
AGGATAGTTT and vegfcrev 50-AAACTCTTTCCCCAC
ATCTA.
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed as
described [55]. The mt2 probe was amplified from 24 hpf
zebrafish embryo cDNA with the T7 promoter site and the
following primers: mt2fwd 50-GGAACTTTCAAGCTCTT
TGTGG and mt2rev 50-gTAATACgACTCACTATAggGA
CAAAGGACATGGCAGAAAA. The vegfc probe is
already described [53].
Confocal microscopy and in vivo time-lapse analysis
Zebrafish embryos were analyzed with confocal micro-
scopy as previously described, using 1 % agarose embryo
moulds [56]. The fluorescent images were acquired using
the Sp5 DM 6000 upright confocal microscope (Leica) or
the inverse LSM 780 confocal microscope (Zeiss).
BrdU incorporation and immunohistochemistry
Proliferation analysis was performed as described [57] with
following modifications: Embryos were grown to 24 hpf
and then incubated in 10 mM 5-bromo-20-deoxyuridine
(BrdU) for 30 min on ice. After 8 h of further incubation
and BrdU incorporation, embryos were fixed in 4 %
paraformaldehyde (PFA) at 32 hpf. After incubation in
2 M HCl for 1 h, permeabilization (phosphate-buffered
saline (PBS) with 0.3 % Triton X-100 (Sigma) and 0.1 %
Tween 20 (Sigma)) and blocking (PBS with 0.3 % Triton
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X-100 and 4 % BSA (Roth)), the following antibodies
were used for immunostaining: mouse anti-BrdU (1:100,
Roche), Alexa 546 anti-mouse (1:500, Invitrogen) and
Alexa 488 anti-GFP (1:500, Invitrogen, for ECs of
Tg(kdrl:EGFP)s843). After each antibody incubation,
extensive washing was performed (PBS with 0.3 % Triton
X-100).
Phenotypic analysis, quantifications, statistics
and softwares
For evaluation of the rescue experiments, different clutches
of at least three different experiments were scored for the
existence of the PHBCs. If the PHBCs were not present at
all or developed to\50 %, they were considered as miss-
ing; if the PHBCs were developed to more than 50 % or
fully connected, they were considered as existent. For
rescue experiments of vegfchu6410 zebrafish mutants, only
embryos with a strong PHBC phenotype or with fully
developed PHBCs were taken for analysis for both Ctr and
mt2 mRNA-injected zebrafish, and each embryo was sub-
jected to subsequent genotyping. Cell numbers of fixed
Tg(kdrl:EGFP)s843 or Tg(fli1a:nEGFP)y7 zebrafish
embryos were evaluated with help of the Spots function of
Imaris. Cells in the PHBC, the anterior cluster and the
posterior clusters were counted at 32 hpf in confocal
stacks. Similarly, ECs of the ACV, PCV and CCV were
counted at 32 hpf, while ECs of the Ses were counted at
48 hpf.
For analysis of the amount of proliferating cells in the
CCVs, BrdU-positive cells were calculated relative to the
total number of ECs in the CCVs. For quantifying the Ses,
the region between somites 9 and 14 has been analyzed.
The P values for the experiments were calculated with a
two-tailed Student’s t-test. The rescue experiments for the
PHBC phenotypes were evaluated for significance with the
Chi-Square test using Microsoft excel. SDS 2.3 and RQ
Manager (Applied Biosystems) were taken for analysis of
the real-time data. Primers were designed using Primer3
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/input.htm).
Where possible, the analysis was performed blind to
experimental conditions.
Results
Mt2 regulates EC behavior during angiogenesis
To identify regulators of EC migration, we screened for
functional involvement of candidate genes using mor-
pholino antisense oligonucelotides (MO) to knockdown
protein expression in zebrafish embryos and analyzed their
vascular development using endothelial-specific GFP
expression (Tg(kdrl:GFP)s843).
We identified Mt2 as a potential regulator of EC
migration. For a detailed analysis, we injected MOs either
inhibiting mRNA translation (using MO covering the
ATG) or blocking mRNA splicing (spbMO). Embryos
injected with mt2 MO or mt2 spbMO, showed brain
necrosis but no other major morphological defects (Fig. 1).
Of the affected vessels, the PHBCs are the first to develop.
They grow by angiogenic sprouting out of an anterior
cluster and a posterior cluster of ECs, which start at 18 hpf
to migrate toward each other and connect around
22–23 hpf to form a functional vessel (Fig. 1d, e; movie 1).
At 24–25 hpf, circulation starts and blood flow can be
observed going through the PHBCs. However, we observed
not only defective growth of the PHBCs, but also of the
CCVs and the Ses at different time points of development
(Fig. 1, Fig. S1).
We used in vivo time-lapse imaging to further analyze
PHBC formation in control MO (Ctr)- or mt2 MO-injected
Tg(kdrl:EGFP)s843 embryos. The Ctr and mt2 MO-injected
(morphant) embryos were indistinguishable from each other
until 18 hpf (Fig. 1e, f), with both displaying normal
development of the lateral dorsal aorta (LDA). In Ctr mor-
phants, the ECs migrated, connected and thereby formed the
PHBCs (Fig. 1e, movie 1), whereas mt2 morphant ECs
failed to migrate out of the clusters and did not connect to
form the PHBC (Fig. 1f, movie 2). However, the ECs were
motile and formed filopodia, but the directed migration
required for the connection of the PHBCs was perturbed
(movie 2). Some mt2-deficient embryos extended sprouts
from the anterior and posterior cluster to develop the
PHBCs, but no proper connection was established. To
determine, whether this defect is caused by defective
migration or reduced EC numbers, we counted the number
of ECs in the PHBCs as well as in the anterior and posterior
cluster at 32 hpf, long after PHBC formation should have
been completed. While the total EC number in PHBCs and
clusters was similar, Ctr morphants had an average of 21
cells in the PHBC and 12 cells in the clusters, whereas mt2
morphants had an average of 13 cells in the PHBC and 22
cells in the cluster (Fig. 1g). Therefore, our results indicate
thatMt2 regulates ECmigration during PHBC angiogenesis.
Additionally, we analyzed CCV formation in Ctr and mt2
morphants in more detail (Fig. S1). The CCVs grow at a
90 C angle out of the trunk ACV and posterior PCV, by a
combination of collective EC migration and proliferation
[13]. At 32 hpf the total cell number in ACV, PCV and CCV
was reduced in mt2 morphants compared with Ctr mor-
phants (Fig. S1j). However, the percentage of cells in the
CCV was significantly reduced from 35 % CCV cells in Ctr
embryos to 26 % in mt2-deficient embryos (Fig. S1i). To
test whether Mt2 regulates EC migration or proliferation in
466 Angiogenesis (2015) 18:463–475
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the CCV, we performed proliferation analysis by BrdU
incorporation in mt2 morphants. Proliferation was strongly
decreased in mt2 morphants (Fig. S2).
In sum, our results indicate that Mt2 regulates angio-
genesis, by regulating EC migration in the PHBCs and EC
proliferation during CCV formation.
mt2 zebrafish mutants phenocopy the mt2
morphants
Despite performing extensive control experiments, MOs
have been shown to exhibit off-target effects [58–60].
To verify the phenotype of the mt2 morphants, we used
TALENs [50] to induce double-strand breaks in the mt2
gene. As expected, errors made by the repair machinery
of the cell then led to mutations in the double-strand
break area [50]. Since the mt2 sequence is very short,
we targeted exon 1, which consists of 25 base pairs
(bp) only (Fig. 2a). We identified several different
alleles of mt2 mutations and further analyzed three of
them.
In the mt2mu289 mutant allele only 6 bp were deleted,
which resulted in deletion of the second and third amino
acid of the Mt2 protein (Fig. 2b, S3). The mt2mu290
sequence has two-point mutations and an insertion of 8 bp,
which led to a frame shift and an early stop codon. The
mt2mu292 sequence has a deletion of 15 bp, which lead to a
frame shift and an early stop codon (Fig. 2b, S3). Since the
mutations of mt2mu290 and mt2mu292 are located next to the
start codon and there is no downstream start codon in
frame, the original Mt2 protein sequence should be com-
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Fig. 1 mt2 morphants fail to form the PHBCs. a Schematic illustra-
tion of the vasculature of a 24 hpf old zebrafish embryo with the
location of the PHBC and the adjacent PHBC forming clusters. b, c
Brightfield images of Ctr (b) and mt2 (c) MO-injected zebrafish
embryos at 24 hpf showed no morphological defects, apart from a
mild necrosis in the head. d Schematic illustration of the development
of the PHBC (dark blue) between 17 and 30 hpf. e, f Confocal
micrographs from time-lapse movies showing the development of the
PHBC in zebrafish embryos between 18 and 30 hpf. The vasculature
was visualized by transgenic GFP expression using
Tg(kdrl:EGFP)s843 embryos. In embryos injected with Ctr MO, ECs
migrate from the anterior and the posterior cluster and connect to
form the PHBC before 24 hpf (at around 23 hpf; e). In embryos
injected with mt2 MO ECs fail to migrate and therefore do not form
the PHBCs (f). White arrows indicate the anterior and posterior
migration front of the PHBC. White arrowheads indicate filopodia in
mt2 morphants. g Quantification of EC numbers in Ctr MO-injected
(black bars) or mt2 MO-injected (white bars) and mt2 spbMO-
injected (gray bars) embryos counted from vascular-specific nuclear
GFP expression (Tg(fli1a:nEGFP)y7). While the total EC numbers
were not affected, mt2 MO-injected embryos showed fewer ECs in
the PHBC and more ECs in the clusters. n = 20, *P\ 0.05; n.s., not
significant; error bars indicate standard error of the mean (SEM).
h Analysis of mt2 splicing efficiency in embryos injected with Ctr
MO or mt2 spbMO. RT-PCR analysis showed a 185 bp amplicon in
embryos injected with mt2 spbMO, while functional splicing led to a
91 bp amplicon in Ctr MO-injected embryos. (Color figure online)
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By mating F1 heterozygous carriers of each mt2 allele,
we obtained homozygous F2 embryos. To our surprise, we
only detected very weak phenotypes (data not shown).
Since mt2 is maternally provided [61], we hypothesized
that the maternal mRNA is sufficient to rescue mt2 defi-
ciency during the early developmental stages analyzed.
Therefore, we raised homozygous F2 embryos to adult-
hood. When mating homozygous mt2 mutant fish to obtain
maternal and zygotic mutant (MZ) F3 offspring, we
observed strong morphological and angiogenesis pheno-
types (Fig. 2), phenocopying the mt2 morphants. Both
MZmt2mu290 and MZmt2mu292 mutants failed to connect the
PHBCs, had reduced cell numbers in the CCVs and
defective Ses formation. (Fig. 2e, f; Fig. S4). Additionally,
in a subset of mt2 mutant embryos the morphology of the
PHBC clusters was affected, with the ECs forming ectopic
sprouts (arrowhead, Fig. 2e). The MZmt2mu289 zebrafish
mutants, which lack only two amino acids, displayed only a
very weak phenotype. The PHBCs (Fig. 2d) and the Ses
(Fig. S4g) developed normally in those mutants, while a
mild phenotype could be observed in the CCVs (Fig. S4b).
The penetrance and severity of the phenotype for both null
mutants were variable within the clutch and between clut-
ches. MZmt2mu290 zebrafish mutants showed severe pheno-
types at higher rates than MZmt2mu292 zebrafish mutants
(compare Table 1), although both should not retain any
amino acid sequence of Mt2. In order to investigate whether
the mutations were causing strong alleles, we examined the
level of gene transcription. One mechanism potentially
interfering with mRNA transcript stability in mutants is
nonsense-mediated decay (NMD), whereas MO-mediated
blocking of translation would rather stabilize the transcript.
We therefore subjected 24 hpf-old MZmt2 mutant
embryos to in situ hybridization to analyze the presence of
a
TGTGGATACTCTCTGGAAAAATGGACCCCTGCGAATGTGCCAAGAGTAAG
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Fig. 2 TALEN-generated mt2 zebrafish mutants fail to form the
PHBC and have different levels of NMD of mt2 transcripts. a 50 and
30 TALEN arms were designed to target exon 1 of the mt2 gene to
induce mutations in the genome. b TALEN injection resulted in
various genomic mutations. Illustrated is the comparison of the amino
acid sequence in WT and different Mt2 mutant alleles, red color
indicates mutated amino acids. In mt2mu289 mutants a 6 bp deletion
resulted in deletion of two amino acids, while in mt2mu290 and
mt2mu292 frameshift mutations resulted in complete changes of the
amino acid sequence. c–f Confocal images of the PHBCs at 24 hpf.
WT (c) and MZmt2mu289 mutant zebrafish embryos (d) form a PHBC,
while MZmt2mu290 and MZmt2mu292 mutant embryos fail to connect
the PHBCs. The vasculature was visualized by transgenic GFP
expression from Tg(fli1a:EGFP)y1 for MZmt2mu289 and MZmt2mu290
mutant embryos and from Tg(kdrl:EGFP)s843 for MZmt2mu292 mutant
embryos. White arrows indicate the anterior and posterior migration
front of the PHBC. mt2 expression was analyzed by in situ
hybridization in 24 hpf-old embryos. While WT siblings (g) and
MZmt2mu289 mutants (h) had similar mt2 expression levels, nonsense-
mediated decay led to degradation of mt2 mRNA transcript in
MZmt2mu290 (i) and MZmt2mu292 (j) mutant embryos. Black arrows
indicate mt2 expression in cells of the yolk extension, black
arrowheads label the region of the PHBCs. k–n Brightfield images
of WT, MZmt2mu289, MZmt2mu290 and MZmt2mu292 mutant embryos
at 24 hpf. WT siblings and MZmt2mu289 displayed no morphological
defects. MZmt2mu290 and MZmt2mu292 mutant embryos are smaller in
size and display necrosis in the head
468 Angiogenesis (2015) 18:463–475
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the mt2 transcript. While WT and MZmt2mu289 mutant
embryos expressed mt2 as published [61], almost no
expression could be observed in MZmt2mu290 and
MZmt2mu292 mutants (Fig. 2g–j). Interestingly, the effi-
ciency of NMD was not the same for both null mutants.
While the great majority of MZmt2mu292 embryos com-
pletely lacked mt2 expression (Fig. 2j), some MZmt2mu290
mutant embryos retained mt2 message partially (Fig. 2i),
which correlated with the different frequencies of angio-
genesis defects (Table 1). We hypothesized that the more
efficient theNMDwas for themt2 zebrafishmutant, themore
compensation mechanisms might take place to attenuate the
phenotype. To analyze, whether mRNA stability could
indeed influence the phenotypic severity, we partially abla-
ted two subunits of the NMD mediating complex (smg1 and
upf1) by injecting smg1/upf1MOs inWT and inMZmt2mu290
mutant embryos.We could indeed observe an increase in the
number of affected embryos, when message degradation by
NMD was reduced (Fig. S5). This indicates that indeed the
correlation of the stronger phenotype with the reduced
mRNA degradation is functionally relevant. The sum of this
data implies that different levels of mRNA degradation can
lead to differences in the phenotypes of generated zebrafish
mutants and morphants, potentially by regulating unknown
compensatory mechanisms.
Mt2 acts upstream of Vegfc in regulating
angiogenesis
Mt2 deficiency resulted in angiogenic defects during PHBC
and CCV formation. Both of these processes have been
described to be regulated by Vegfc during zebrafish
embryonic development. Vegfc mutants or morphants fail
to connect the PHBCs and have reduced proliferation in
their CCVs [11, 13].
We therefore carried out different rescue experiments to
analyze whether there is an interaction of Mt2 and Vegfc
signaling. We ubiquitously overexpressed Vegfc in WT or
mt2 morphant embryos by injection of vegfc mRNA into
1-cell-stage embryos. Overexpression of vegfc in WT
embryos did not alter EC migration to form the PHBCs
(Fig. 3a), but significantly reduced the number of embryos
with PHBC connection defects from 44 % affected mt2
morphants to 25 % affected vegfc-injected mt2 morphants
(Fig. 3c, j, n). Furthermore, we overexpressed the Vegfc
ligand trap sflt4 [54], which is a soluble form of the Vegfr3,
that titrates away Vegfc and therefore results in the same
phenotypes as the genetic vegfc mutation (Fig. 3e, k). By
combining sflt4 with high amounts of mt2 mRNA injection,
we could compensate the PHBC formation failure (Fig. 3f,
k, o). Injection of vegfc mRNA rescued the sflt4 mRNA
injection to a similar extent (data not shown), indicating
that Mt2 overexpression could indeed compensate for
Vegfc ligand depletion. Interestingly, when we repeated
the same experiment of rescuing Vegfc deficiency by mt2
overexpression in vegfchu6410 mutant embryos, Mt2 failed
to rescue (Fig. 3i, l, p), suggesting that vegfc is the only
relevant target of mt2. We confirmed the upregulation of
vegfc transcripts after mt2 mRNA injection in vegfchu6410
mutant embryos with qPCR (Fig. S6). Taken together our
data showed that Mt2 deficiency can be overcome by
Vegfc addition and that Mt2 overexpression can outcom-
pete Vegfc protein depletion, but not Vegfc mutation.
These results are consistent with a mechanism, in which
Mt2 regulates vegfc RNA expression (Fig. 3m).
Mt2 regulates transcript levels of vegfc
Given the results above, we used qPCR to analyze vegfc
transcript levels in mt2 morphant, MZmt2mu290 mutant and
mt2-overexpressing embryos. qPCR analysis revealed a
20 % decrease in vegfc RNA in mt2 morphants and a 31 %
decrease in MZmt2mu290 mutant embryos (Fig. 4a). mt2
overexpression on the other hand led to a 27 % increase in
vegfc RNA levels in zebrafish embryos (Fig. 4a). To test
whether vegfc transcripts are specifically affected, we
analyzed further genes in mt2-deficient and mt2-overex-
pressing embryos. We chose fli1a as an EC-specific gene
and myod1, a muscle-specific marker to represent other
tissues [62]. We observed no significant changes in either
fli1a or myod1 transcript levels, irrespective of the mt2
expression level. In contrast the significant changes in
vegfc transcripts correlated with the changes in mt2
expression as vegfc levels were decreased in mt2-deficient
Table 1 mt2 zebrafish morphants, MZmt2 zebrafish mutants and
vegfchu6410 zebrafish mutants display many common phenotypes
PHBCs Clusters Ses CCVs
WT 0 2.26 2.53 4.75
mt2 MO 79.07 92.78 94.29 84.76
mt spbMO 75.00 85.71 90.24 77.78
MZmt2mu289 0 3.64 6.50 18.20
MZmt2mu290 34.22 84.42 90.37 41.63
MZmt2mu292 8.02 35.73 68.75 26.78
vegfchu6410 59.52 7.50 6.34 65.00
Overview of the frequencies of the different phenotypes observed
upon mt2 deficiency compared to vegfc deficiency and WT zebrafish
embryos. The following classification of phenotypes was scored as
affected: PHBCs: The PHBCs were developed to less than 50 % in
length; cluster: severely thickened anterior cluster or additional
ectopic sprouts or holes; CCVs: reduction by more than 15 % of EC
numbers; Ses (scored between somites 9 and 14): Se sprouts were
either significantly shortened by more than 15 % or Se numbers were
reduced to less than 85 %. The PHBC, cluster and Se phenotypes
were analyzed at 24 hpf; the CCVs were analyzed at 32 hpf (WT
n = 138, vegfchu6410 n = 93, mt2MO n = 168, mt2 spbMO n = 157,
mt2mu292 n = 256, mt2mu290 n = 128, mt2mu289 n = 123)
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Fig. 3 Mt2 acts upstream of Vegfc in PHBC formation. a–c,
j Injection of vegfc mRNA rescued mt2 deficiency in mt2 morphants.
Overexpression of vegfc mRNA does not disturb PHBC formation (a).
Upon mt2 MO injection (b), 44 % of the embryos lack the PHBC,
while upon co-injection with vegfc mRNA (c) PHBC formation
becomes rescued in half of the affected embryos (quantification of
different experiments shown in j). d–f, k mt2 overexpression rescued
PHBC formation defects induced by overexpression of a Vegfc ligand
trap (sflt4 overexpression). Injection of mt2 mRNA resulted in normal
PHBC development (d). Depletion of Vegfc through injection of sflt4
mRNA led to a failure in PHBC formation in 68 % of the embryos
(e). Co-injection of both mt2 and sflt4 mRNA rescued PHBC
formation and left only 23 % of embryos showing no PHBC
(quantifications of different experiments shown in k). g–i,
l Overexpression of mt2 mRNA in embryos with a genetic null
mutation in the vegfc gene (vegfchu6410) could not rescue the PHBC
phenotype. Embryos were scored for their phenotype and subse-
quently genotyped for the vegfc mutation (quantifications of different
experiments shown in l). The analysis was performed using
Tg(kdrl:EGFP)s843 (a–f) and Tg(fli1a:EGFP)y1 (g–i) embryos. j–
k Quantifications of the phenotypes observed after injection of
indicated reagents: Black bars label percent of embryos with the
PHBC formed, white bars label percent of embryos lacking the
PHBC. Statistical significance was calculated with the Chi-square
test, n = 228 (j), n = 277 (k), n = 124 (l), **P\ 0.01;
***P\ 0.001; n.s., not significant. m–p Schematics representing
the proposed mechanisms of angiogenesis regulation in the experi-
ments shown in a–l
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and increased in mt2-overexpressing cells (Fig S6). The
analysis of vegfc RNA transcript levels via in situ
hybridization showed similar results in some domains of
vegfc expression (Fig. 4b–d). mt2 morphants show reduced
vegfc staining, especially in the region, where the PHBCs
develop (Fig. 4c, arrowheads). Interestingly, the increase in
vegfc RNA expression in mt2-injected embryos was also
confined to specific domains, including the region of PHBC
development (Fig. 4b–d, arrowheads), but not ubiquitously
distributed (Fig. 4d). Therefore, our results show that Mt2
is required for regulating vegfc, e.g., during PHBC for-
mation, but it is not sufficient to induce general vegfc
expression ectopically. This can be further substantiated
when comparing the WT expression patterns of vegfc and
mt2, showing that some domains of vegfc expression are in
the same region as mt2 expression, while there are also
vegfc expression domains in areas not expressing high
amounts of mt2 (Fig. S6). We claim that the regulation of
vegfc via Mt2 is specifically confined to specific vascular
niches, such as the region of PHBC formation.
Other metallothioneins cannot regulate vegfc
expression
To get more mechanistic insight how Mt2 could regulate
vegfc expression, we questioned whether vegfc expression
regulation could be a consequence of a cellular stress and
hence would require the detoxifying features characteristic
to all Metallothioneins (Mts). Therefore, we performed
knockdown and overexpression experiments using another
Metallothionein family member, metallothionein-B-like
(mtbl; Fig. 5). To analyze mtbl-deficient embryos, we used
again both translation and splice blocking MOs for our
analysis and validated the functionality of the spbMO using
RT-PCR (Fig. 5c). Even though mtbl deficiency led to
defective development of the CCVs and Ses (Fig. S7), mtbl
morphants showed normal PHBC development (Fig. 5b),
indicating that during normal embryonic development Mt2
is specifically required for regulating vegfc expression. We
next analyzed whether, as shown for Mt2, excess amounts
of ectopic Mtbl could compensate for Vegfc ligand
depletion by the ligand trap sflt4. While injection of sflt4
mRNA again provoked defective PHBC development
(Fig. 5e), co-injection with mtbl mRNA did not rescue this
phenotype (Fig. 5f, g). Furthermore, vegfc transcripts were
not significantly changed upon knockdown of mtbl
(Fig. 5h). These results indicate that the regulation of vegfc
transcription by Mt2 is not based on its Metallothionein
characteristics and therefore not part of a cellular stress
response, but rather represents an additional specific
function of Mt2.
Discussion
In this study, we showed that Mt2 regulates developmental
angiogenesis in zebrafish by regulating vegfc mRNA
expression. Vegfc regulates EC migration as a chemoat-
tractant, e.g., by guiding ECs in the PHBCs [9, 11], and
indeed, we show that correct migration of the PHBCs was
perturbed by deletion of mt2. Additionally, Vegfc regulates
EC proliferation [13], which was also perturbed in mt2-
deficient zebrafish embryos.
We analyzed the role of Mt2 in zebrafish angiogenesis
using MO-mediated Mt2 ablation as well as by using
TALENs to introduce mutations in the zebrafish mt2 gene.
While we observed the same phenotypes in morphants as
well as mutants, the phenotypes occurred at different fre-
quencies between morphants and even between different
hypothetical null mutants of mt2 (see Table 1). Multiple
mechanisms have been discussed to explain differences
between mutant and morphant phenotypes: reinitiation at a
downstream AUG or at an alternative start codon, exon
skipping or the upregulation of other compensatory genes
[63]. From the mt2 sequence we can exclude reinitiation at
a downstream AUG or exon skipping as potential mecha-
nisms. We cannot predict whether there would be reiniti-
ation at non-AUG start codons. However, we here provided
a detailed analysis demonstrating that differences in
mRNA stability, caused by NMD-mediated decay of the
transcript, might account for the variability of the observed
mt2 MO
dc




























Fig. 4 Mt2 regulates transcript levels of vegfc. a qPCR analysis of
vegfc transcript levels (a) in mt2 morphants, MZmt2mu290 mutants and
mt2 mRNA-injected embryos compared to Ctr embryos. Both
morphants and mutants showed a significant decrease in vegfc
transcript levels, while overexpression of mt2 led to an increase in
vegfc transcripts. n = 3, *P\ 0.05; **P\ 0.01; error bars represent
SEM; b–d in situ hybridization for vegfc in hpf embryos injected with
mt2 MO or with mt2 mRNA showed a reduction in vegfc expression
upon knockdown of mt2 (c) and an increase after mt2 mRNA
injection (d)
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phenotypes. Our experiments show that a stronger effi-
ciency of NMD led to a weaker penetrance of the pheno-
type, which might indicate transcript-level-based
regulation of compensatory mechanisms in the embryo.
Additionally, even vegfc null mutants do not show full
penetrance in failing to form the PHBC (Table 1, supple-
mentary material [11]); therefore, embryos with a reduction
in vegfc expression through mt2 deficiency are not likely to
display higher phenotypic frequencies.
In our study we identified a role for Mt2 in regulating
angiogenesis upstream of transcriptional regulation of
vegfc expression.
While in the zebrafish only two mt genes exist, in
mammals there are at least four different gene families
with differentially expressed isoforms [64]. Analysis of the
amino acid sequence via UniProt revealed highest identity
of the zebrafish Mt2 to the human and mouse MT1, closely
followed by the human and mouse MT2. Mammalian Mt1
and Mt2 are supposedly very similar in their function [26]
and have previously been implicated to be involved in
angiogenic processes. The MZmt2 zebrafish knockout led
to impaired development of major vessels, such as the
PHBCs, the CCVs and the Ses and MZmt2-deficient
embryos died during larval stages. The murine Mt1/2
double knockout in contrast was viable [36] and only dis-
played angiogenesis defects when challenged, e.g., by
cortical freeze injury or femoral artery ligation [38–40]. As
in zebrafish maternal message was capable of compensat-
ing mt2 deficiency during embryonic angiogenesis, most
likely in mammals other MT family might be able to
24 hpf
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Fig. 5 The mt2 paralogue metallothionein-B-like (mtbl) does not
regulate PHBC formation. mtbl MO-mediated deficiency does not
affect PHBC formation. Tg(kdrl:EGFP)s843 embryos showed normal
PHBC development at 24 hpf after injection of Ctr MO (a) or mtbl
translation blocking MO (b). c Analysis of mtbl splicing efficiency in
embryos injected with Ctr MO or mtbl spbMO. RT-PCR analysis
showed a 327 bp amplicon in embryos injected with mtbl spbMO,
while functional splicing led to a 169 bp amplicon in Ctr MO-injected
embryos. mtbl overexpression failed to rescue PHBC formation
defects induced by overexpression of a Vegfc ligand trap (sflt4
overexpression). Overexpression of mtbl via mRNA injection (d) re-
sulted in normal development of the PHBC, while sflt4 mRNA
injection resulted in PHBC formation failure (e). This phenotype
could not be rescued through co-injection of mtbl mRNA (f).
Quantification comparing the percentages of embryos lacking the
PHBC, with n = 350, ***P\ 0.001; n.s., not significant (g). The
analysis was done with Tg(kdrl:EGFP)s843 embryos. h qPCR analysis
of mtbl morphants showed no significant increase in the vegfc
transcript. Error bars show SEM; n.s., not significant
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compensate Mt1/2 deficiency during development. How-
ever, a link to angiogenesis has also been established for
human Mts in vitro [65].
We demonstrated that Mt2 but not Mtbl regulates
angiogenesis upstream of vegfc transcription. Mt family
members are involved in regulating a large number of
developmental processes, including cell survival, cell pro-
liferation, migration, scavenging of reactive oxygen spe-
cies, and modulating the immune response. Most of these
capabilities have been attributed to the metal-binding
capabilities, resulting, e.g., in removal of cofactor ions such
as zinc [26, 30, 66]. The zebrafish Mtbl is capable of ful-
filling these MT family member functions, but does not
rescue PHBC development in mt2 morphants or vegfc
ligand reduced embryos. We present here the first evidence
for an additional role of zebrafish Mt2 in regulating vegfc
expression independent of Mt function. Interestingly,
upregulation of different human MT isoforms was
observed comparing the responses to physiological or
hypoxic conditions [65]. This could be taken as an indi-
cation for differential regulatory functions of some human
MT family proteins, independent of the functions common
to all MTs.
We analyzed whether other transcript levels were regu-
lated by zebrafish Mt2 in addition to vegfc. Neither the
Vegfc regulator ccbe1 expression, nor the Pdgf/Vegf family
member c-fos-induced growth factor (figf) expression was
altered. In contrast, vegfa expression seemed also regulated
downstream of MT2 (data not shown). Reduced Vegfa RNA
[40] and VEGFA protein levels [38] were reported in Mt1/
2-deficient mice. While changes in Vegfc expression
explained the PHBC and CCV phenotypes, reduction in
Vegfa expression would account for the failures in Se for-
mation, as deficiency in either Vegfa or its receptor Kdrl
result in severe Se phenotypes [9, 67].
In sum, we have identified a novel role of MT2 in
regulating angiogenesis by regulating vegfc transcription,
which might be conserved in mammals.
We for the first time show that this regulatory role is
specific to zebrafish Mt2 and represents a novel, non-
canonical function of MT2, most likely not attributed to
metal-binding capabilities of MT proteins.
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